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Skeletal muscles adapt to increasing workload by
augmenting their fiber size, through mechanisms
that are poorly understood. This study identifies the
cytokine interleukin-6 (IL-6) as an essential regulator
of satellite cell (muscle stem cell)-mediated hypertro-
phic muscle growth. IL-6 is locally and transiently
produced by growing myofibers and associated sat-
ellite cells, and genetic loss of IL-6 blunted muscle
hypertrophy in vivo. IL-6 deficiency abrogated satel-
lite cell proliferation and myonuclear accretion in the
preexisting myofiber by impairing STAT3 activation
and expression of its target gene cyclin D1. The
growth defect was indeed muscle cell intrinsic, since
IL-6 loss also affected satellite cell behavior in vitro,
in a STAT3-dependent manner. Myotube-produced
IL-6 further stimulated cell proliferation in a paracrine
fashion. These findings unveil a role for IL-6 in hyper-
trophic muscle growth and provide mechanistic
evidence for the contribution of satellite cells to this
process.
INTRODUCTION
Loss of muscle mass occurs in multiple settings, including can-
cer, AIDS, cachexia, and neuromuscular disorders, as well as
during aging, remaining an important factor contributing to mor-
bidity. Understanding the molecular pathways that regulate gain
or loss of muscle mass is therefore crucial for treating muscle
wasting-associated disorders. Positive modulation of skeletal
musclemass in response to increased workload results in hyper-
trophy of individual myofibers, but the key molecular mediators
of this process are only beginning to be clarified (Glass, 2005).
Mounting evidence indicates that the endogenous adaptive
growth capacity ofmaturemyofibers is limited to acertain thresh-
old due to the necessity of maintaining equilibrium between the
increased cytoplasmic volume and the genetic machinery. Be-
cause multinucleated myofibers are permanently differentiated
and are incapable of mitotic activity, the acquisition of new ge-
netic material during postnatal muscle growth relies on accretion
of new nuclei provided by a population of self-renewing musclestem cells named satellite cells (Adams, 2006; Dhawan and
Rando, 2005). Satellite cells, located in themuscle basal laminae,
are quiescent but become activated to meet myofiber adaptive
requirements. Indeed, if satellite cells’ dividing capacity is ab-
lated by local irradiation, increases in myonuclear number and
full fiber hypertrophy do not occur in response to increasedmus-
cle loading (Adams et al., 2002; Rosenblatt and Parry, 1992;
Rosenblatt et al., 1994). Once activated, satellite cells follow an
ordered set of events, including proliferation, migration, and in-
corporation into the adult overloaded myofiber, leading to myo-
fiber growth, in a process that can be partially recapitulated in
vitro. In this context, although a number of secreted molecules
have been implicated in the modulation of satellite cell behavior
in vitro and ex vivo, the molecules controlling myonuclear accre-
tion in the myofiber during the growth process in vivo remain
basically unknown. Notably, autocrine/paracrine loops involving
IGF-1 (insulin-like growth factor 1) are able to induce myofiber
hypertrophy by activating PI3K (phosphatidylinositol 3-kinase)/
AKT-dependent pathways (Bodine et al., 2001; Glass, 2005).
The muscle-secreted cytokine interleukin-4 (IL-4) has been
shown to promote muscle regeneration, a process which in-
volves de novo myofiber formation, by specifically stimulating
the fusion of myoblasts with myotubes (Horsley et al., 2003).
Interleukin-6 (IL-6) is a pleiotropic cytokine associated with
the control and coordination of immune responses (Kishimoto,
2005). In addition to the classical cell types known to produce
IL-6 (Kamimura et al., 2003), increasing evidence indicates that
skeletal muscle cells are a further important source of IL-6 (His-
cock et al., 2004; Keller et al., 2001; Penkowa et al., 2003). In vitro
studies have confirmed that IL-6 is produced by human primary
myoblasts and murine C2C12 myogenic cells (Bartoccioni et al.,
1994; De Rossi et al., 2000). Significantly, we have previously
demonstrated that IL-6mRNA knockdown reduces muscle-spe-
cific gene expression in cultured C2C12 myoblasts (Baeza-Raja
and Munoz-Canoves, 2004), suggesting a potential myogenic
role for this cytokine. Since IL-6 is detected locally at elevated
concentrations in actively contracting muscle fibers and after
increased workload (Carson et al., 2002; Hiscock et al., 2004;
Jonsdottir et al., 2000; Keller et al., 2001; Penkowa et al.,
2003), both of which are known to induce satellite cell activities
and stimulate an increase in muscle mass, we hypothesized
a role for this cytokine in adult muscle growth. In this study, we
first analyzed potential differences in growth capacity between
muscles of IL-6+/+ (wild-type, WT) and IL-6/ (IL-6-deficient)
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Hypertrophic Muscle Growth
Plantaris muscles from wild-type (WT) and IL-6/
mice were obtained before surgery from nonover-
loaded controls (C) and after the indicated number
of days of compensatory hypertrophy (CH).
(A) Top: IL-6 expression was analyzed by RT-PCR.
Gapdh expression was used as a control. Bottom:
IL-6 protein expression was analyzed by ELISA.
Concentration (mean ± SD) is expressed as
ng/mg of total muscle protein extract.
(B) Representative images of plantaris muscle
sections stained with hematoxylin and eosin from
WT and IL-6/ mice before (C) and after 3 and
14 days of CH. Scale bar = 50 mm.
(C) Top: immunostaining for IL-6 expression be-
fore (C) and after 3 days of CH in muscles from
WT and IL-6/mice. Scale bar = 50 mm. Bottom:
double immunolabeling for Pax7 (green) and IL-6
(red) in plantaris muscle sections after 3 days of
CH. Arrows indicate Pax7-expressing cells. Scale
bar = 20 mm.
(D) Mean cross-sectional area (CSA) of muscle
fibers before (C) and after 14 and 42 days of CH
in WT and IL-6/ mice. Data are mean ± SEM.
*p < 0.05 versus C.
tinued to be elevated after 3 and 14 days,
decreasing thereafter (Figure 1A). Con-
firming the expected induction of muscle
growth in this model, a significant in-
crease in myofiber cross-sectional area
(CSA) of the plantaris muscle was readily
observed in comparison to control nono-
verloaded muscles 14 days after over-
loading (Figure 1B, see WT panel). Next,
we investigated the specific cellular
source of IL-6 in skeletalmuscle by immu-
nohistochemistry. After overloading, IL-6mice after increasingmechanical load. Second, by using satellite
cells derived from both WT and IL-6/ muscles, we compara-
tively investigated their functional properties in response to
IL-6. Based on our results, IL-6 emerges as an important mole-
cule for muscle hypertrophy by controlling satellite cell prolifera-
tion and myonuclear accretion. Moreover, we uncover a role for
the STAT3 activation pathway in mediating these effects.
RESULTS
IL-6 Deficiency Blunts Hypertrophic Muscle Growth
To investigate the putative role of IL-6 in skeletal muscle growth,
we induced functional overloading of themouse plantarismuscle
by incapacitation of the gastrocnemius muscle and examined
IL-6 expression during the process of compensatory hypertro-
phy (CH) of theplantaris at different timepoints. In nonoverloaded
control muscles, IL-6 expression was almost undetectable at
the mRNA and protein levels in the basal state (Figure 1A). In
contrast, IL-6 expression was induced after 1 day of CH and con-expression was clearly associated with both hypertrophying my-
ofibers and mononucleated interstitial cells, including basal
membrane-associated satellite cells, as shown by double label-
ing with specific antibodies for IL-6 and Pax7 (a satellite cell-spe-
cific marker) (Figure 1C). As a control, no IL-6 expression was
detected in overloaded plantaris muscles from IL-6/mice (Fig-
ure 1C). Altogether, these results demonstrate a muscle-specific
induction of IL-6 during hypertrophic growth.
To investigate the relevance of IL-6 in this process, we as-
sessed potential differences in muscle growth between IL-6/
andWTmice after overloading bymorphometric analyses. Com-
pared to WT mice, no significant increase in myofiber CSA was
observed in IL-6/ mice at 14 and 42 days after overloading
(Figure 1D), indicating that IL-6 is necessary for myofiber hyper-
trophic growth. However, loss of IL-6 did not affect the baseline
CSA of nonoverloaded plantaris myofibers (Figure 1D) or myo-
fiber number (WT, 795 ± 132; IL-6/, 751 ± 43; mean ± SD,
p > 0.05), indicating that IL-6 is not required for muscle formation
or basal maintenance of myofiber size.
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tory Hypertrophy Is Attenuated in IL-6/ Mice
Plantarismuscles were obtained fromWT and IL-6/mice before and
after the indicated number of days of CH.
(A) Phosphorylated AKT, total AKT protein, and phosphorylated
p70S6K were analyzed by western blotting using specific antibodies.
Ponceau red was used as a loading control.
(B) Top: representative immunostaining for dystrophin (red) and nu-
clear staining with DAPI (blue) to illustrate myonuclear number assay.
Scale bar = 20 mm. Bottom left: numbers of DAPI-stained nuclei within
the dystrophin-positive sarcolemmawere counted before (C) and after
14 and 42 days of CH and are expressed per 100 myofibers. Bottom
right: the cytoplasm/nucleus ratio before and after muscle overloading
is expressed as the number of DAPI-stained nuclei within the dystro-
phin-positive sarcolemma per mm2. Data are mean ± SD. *p < 0.05
versus C.
(C) Left: Pax7 mRNA expression was analyzed by RT-PCR in control
plantaris muscles from WT and IL-6/ mice. Gapdh mRNA expres-
sion was used as a control. Right: identification of satellite cells by
Pax7 immunostaining (arrow) in control plantaris muscles. Scale
bar = 20 mm.
paired increase in CSA of IL-6/ myofibers results from
defects in satellite cell-derived myonuclear accretion in
the preexisting myofiber. Of note, the cytoplasm/nucleus
ratio (expressed as myonuclei/mm2) did not change sig-
nificantly throughout thehypertrophicprocess (Figure2B).
In addition, no differences in satellite cell number at mus-
cle basal state (as determined by quantification of Pax7-
positive cells) were found between WT and IL-6/ mice
(satellite cells/100 fibers: WT, 2.27 ± 0,41; IL-6/,
3.17 ± 0.06; mean ± SEM, p > 0.05). In agreement with
this, Pax7 mRNA expression in control muscles from
both genotypes was also similar (Figure 2C). These data
provide direct in vivo evidence for the function of mus-
cle-produced IL-6 in the myonuclear accretion occurring
during myofiber hypertrophy.Reduced Myonuclear Numbers
in Overloaded IL-6-Deficient Myofibers
Since hypertrophic muscle growth is known to be regulated by
protein synthesis pathways, such as the PI3K/AKT pathway
(Glass, 2005), we comparatively analyzed the activation of AKT
and its downstream mediator p70S6K in WT and IL-6/muscles
at different time points during CH. As expected, both AKT ex-
pression and activation levels were induced during CH (Fig-
ure 2A); likewise, p70S6K was also activated during CH (Bodine
et al., 2001) (Figure 2A). Notably, no differences in activated
AKT and p70S6K were observed between overloaded muscles
from WT and IL-6/ mice, indicating that IL-6 is not required
for the activation of the protein synthesis- and growth-associ-
ated PI3K/AKT pathway during CH and suggesting that IL-6
might affect satellite cell incorporation into hypertrophying myo-
fibers. To this end, myonuclear number was assessed in control
and overloaded WT and IL-6/ plantaris muscle by determining
the number of DAPI-stained nuclei within the dystrophin-stained
sarcolemma (Figure 2B, top). A 40% increase in myonuclei num-
ber was observed in WT plantaris muscles at 14 days of CH and
wasmaintained at 42 days, while no significant increase was ob-
served in IL-6/ muscles (Figure 2B), suggesting that the im-IL-6 Loss Reduces Satellite Cell Proliferation
Since activation of satellite cells and their subsequent prolifera-
tion are necessary steps prior to the ultimate addition of myonu-
clei to growing myofibers (Darr and Schultz, 1989; Rosenblatt
and Parry, 1993) and since local IL-6 induction occurred soon
after overloading (at 1–3 days) (Figure 1A), we postulated that
the reduced myonuclear number and CSA of IL-6/ myofibers
might result from defects at the early myogenic stages of the
CH process in the absence of IL-6. To analyze the consequences
of IL-6 loss on satellite cell activation and proliferation in vivo,
we quantified the number of satellite cells expressing MyoD
(a marker of activated satellite cells) and phosphorylated histone
H3 (p-H3) (a marker of cells in S phase) in WT and IL-6/ mus-
cles 3 days after overloading. In basal conditions, the number of
quiescent satellite cells was similar in both genotypes (see
above), while no expression of MyoD was detected in WT or
IL-6/ muscles (data not shown). Muscle overloading induced
the activation of satellite cells, as detected by the induced ex-
pression of MyoD with respect to control muscles, to a similar
extent in both genotypes (Figure 3A). However, the number of
cells double-positive for MyoD and p-H3 was severely reduced
in IL-6/ overloaded muscles (Figure 3B). Confirming thell Metabolism 7, 33–44, January 2008 ª2008 Elsevier Inc. 35
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Proliferation after Muscle Overloading
Sections of plantaris muscles obtained from WT
and IL-6/mice 3 days after overloading were im-
munostained with antibodies against MyoD and
phosphorylated histone H3 (p-H3). Nuclei were
detected with DAPI.
(A) Quantification of the number of MyoD-positive
cells per mm2. Data are mean ± SD.
(B) Top: double immunostaining for MyoD (green)
and p-H3 (red) in muscle sections. Scale bar =
20 mm. Bottom: percentage of total MyoD-positive
cells coexpressing p-H3 in both genotypes. Ar-
rows indicate MyoD-positive cells. Data are
mean ± SD.
(C) Top: double immunostaining for BrdU (red) and
dystrophin (green) and nuclear staining with DAPI
(blue) in muscle sections from WT and IL-6/
mice before (C) and after 3 days of CH. Middle:
higher magnification of BrdU and dystrophin im-
munostaining is shown. Bottom: BrdU-positive
cells per mm2 were quantified in WT and IL-6/
plantaris muscle sections after 3 days of CH. Scale
bar = 20 mm. Data are mean ± SEM.
*p < 0.05 versus WT.
myotubes in vitro (see Figures S1A and
S1B available online), in agreement with
the in vivo expression in satellite cells
and growing myofibers (Figure 1C). Since
no clear evidence for the presence of the
IL-6 receptor complex in muscle cells has
yet been provided, we investigated the
expression of the IL-6 receptor complex
components gp130 and IL-6Ra in muscle
cells. Indeed, transcripts of both compo-
nents as well as membrane-bound IL-
6Ra protein were expressed in primary
and C2C12 muscle cells (Figures S1C–
S1E). Interestingly, IL-6 loss did not affect
the expression of IL-6Ra in IL-6-deficient
cells (Figures S1E and S1F). Furthermore,defective proliferation in the absence of IL-6, bromodeoxyuridine
(BrdU) administration to IL-6/ and WT mice after overloading
showed cells in S phase (BrdU+) outside of the dystrophin outline
in plantaris muscle of both WT and IL-6/ mice at 3 days after
overloading, but not in control nonoverloaded muscles; notably,
the number of BrdU-positive cells was strongly reduced in the
absence of IL-6 after CH (Figure 3C). Together, these data dem-
onstrate that IL-6 is dispensable for satellite cell activation but is
critical for satellite cell proliferation during CH; hence, the im-
paired proliferation in the absence of IL-6 may impede new
myonuclear accretion in growing myofibers.
IL-6 Regulates Myoblast Proliferation and Migration
To further investigate whether the in vivo growth defects in the
absence of IL-6 are muscle cell intrinsic, we examined satellite
cell-derived primary myoblast functions in vitro. RT-PCR and
ELISA analyses showed that IL-6 transcript and protein were
expressed by proliferating primary myoblasts and by growing
36 Cell Metabolism 7, 33–44, January 2008 ª2008 Elsevier Inc.IL-6Ra was also detected in plantaris muscle membrane ex-
tracts (Figure S1G). Additionally, we demonstrate that shedding
of the receptor, which has been reported in other cell types
(Rose-John, 2003), also occurs in muscle cells. Indeed, western
blotting analysis of primary and C2C12myoblast cell culture me-
dia and plantaris muscle extracts revealed the presence of the
soluble 50 kDa IL-6Ra (sIL-6Ra) (Figures S1H and S1I). Thus,
IL-6 may signal in muscle cells through both the cell-surface-
associated and soluble forms of IL-6Ra.
Based on the synthesis of IL-6 by both satellite cells and grow-
ing myofibers in vivo, we hypothesized potential autocrine and/
or paracrine actions of IL-6 on satellite cell proliferation. To ad-
dress the autocrine role of IL-6, we analyzed the differences in
proliferation rates between WT and IL-6/ myoblasts by deter-
mining the incorporation of BrdU. IL-6/ cells exhibited an
50% reduction in the rate of proliferation compared toWT cells
(Figure 4A); importantly, the proliferation deficit was rescued by
addition of recombinant IL-6 (rIL-6). This result argued against
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gene in myoblasts. Furthermore, C2C12 myoblasts stably ex-
pressing IL-6 (C2/IL-6) also exhibited a higher proliferation rate
than mock-transfected C2C12 cells (Figure S2A). The potential
paracrine action of growing myofiber-produced IL-6 on satellite
cell proliferation was addressed in vitro by determining the BrdU
incorporation rate of IL-6/ myoblasts in response to condi-
tioned medium (CM) from WT and IL-6/ growing myotubes.
CM from IL-6/ myotubes stimulated myoblast proliferation to
a lesser extent than CM from WT myotubes (Figure 4B). Thus,
IL-6 is necessary for adequate myoblast proliferation in vitro, in
agreement with the in vivo proliferation defect observed in over-
loaded muscles of IL-6-deficient mice. Moreover, these findings
underscore the contribution of both myoblast- and myofiber-
produced IL-6 to the proliferation of muscle cells during the
growth process.
Proliferating satellite cells must migrate and establish stable
cell-fiber contacts for accretion of myonuclei. Thus, we analyzed
the contribution of IL-6 to myoblast migration by using standard
transwell migration assays. As shown in Figure S3A, migration of
primary myoblasts from IL-6/mice was reduced compared to
WT cells, while supplementation with rIL-6 rescued this defect.
The extent of migration was also higher in C2/IL-6 myoblasts
compared to C2C12 control cells (Figure S3B). Moreover, CM
from WT myotubes stimulated the migration of WT or IL-6/
myoblasts to a greater extent than IL-6/ myotube CM (Fig-
Figure 4. IL-6 Is Necessary for Myoblast Proliferation
Satellite cell-derived primary myoblasts from WT and IL-6/ mice were ana-
lyzed.
(A) Percentage of BrdU-positive cells in WT and IL-6/ primary myoblasts
treated without (left two columns) or with (right two columns) rIL-6. *p < 0.05
versus untreated WT.
(B) Relative proliferation rates of WT and IL-6/myoblasts in the presence of
conditioned medium (CM) from WT or IL-6/ myotubes, expressed as prolif-
eration rate with respect to each cell type in the presence of nonconditioned
medium, which was arbitrarily given a value of 1. *p < 0.05 versus control.
Data are mean ± SD.ure S3C). These in vitro results support the idea that migratory
defects of myoblasts in the absence of IL-6 may also contribute
to the reducedmyonuclear number and size of overloaded fibers
in IL-6-deficient mice.
Role of STAT3 in IL-6-Induced Myoblast
Proliferation and Migration
To gain mechanistic insights into how IL-6 controls myoblast
functions, we first examined potential differences in the activa-
tion of IL-6-responsive signaling pathways in WT and IL-6/
myoblasts. ERK and PI3K/AKT pathways have been previously
implicated in myogenesis (Forcales and Puri, 2005; Mourkioti
and Rosenthal, 2005), and both pathways can be activated by
IL-6 in certain cell types (Ernst and Jenkins, 2004). On the other
hand, the JAK/STAT3 pathway is a major route activated by IL-6,
especially in inflammatory cells (Kamimura et al., 2003), although
its implication in myogenesis has remained unclear. We there-
fore analyzed the activation of these three pathways in myo-
blasts expressing or lacking IL-6 using anti-phosphospecific
antibodies for the activated forms of ERK, AKT, and STAT3, re-
spectively. The levels of activated STAT3 were much lower in
IL-6/ myoblasts than in WT cells, and, importantly, they were
rescued by exogenous rIL-6 (Figure 5A), indicating a muscle-
intrinsic modulation of STAT3 activity by IL-6. Addition of rIL-6
(Figure 5A) or CM fromWTmyotubes (data not shown) further in-
creased the activation of STAT3 inWTmyoblasts, supporting the
idea of a paracrine action of IL-6 inmyoblast signaling via STAT3.
At variance with these results, no significant differences in ERK
and AKT activation were detected between cells expressing or
lacking IL-6 or in response to exogenous IL-6 (Figure 5A). These
results suggested that the activation of STAT3—rather than
activation of AKT and ERK—by IL-6 could underlie its control
of myoblast proliferation and migration.
To test this possibility, WT myoblasts were cultured in the
absence or presence of AG490, an inhibitor of the JAK/STAT3
pathway, and wortmannin, an inhibitor of the PI3K/AKT pathway
(used as a negative control) (Figure S4), and cell proliferation and
migration rates were determined. The effects of both inhibitors
on exogenous IL-6-inducedmyoblast proliferation andmigration
were also examined in parallel assays. AG490, but not wortman-
nin, blocked myoblast proliferation and migration both in WT
myoblasts and in rIL-6-treated WT and IL-6/ myoblasts (Fig-
ure 5B; Figure S4B); also, the effect of WT myotube CM on myo-
blast proliferation and migration was blunted by AG490, but not
by wortmannin (Figure 5C; Figure S4C), suggesting that STAT3
activation is a major contributor to the autocrine and paracrine
effects of IL-6 on myoblast proliferation and migration.
To confirm the direct and specific role of STAT3 activation in
these IL-6-mediated processes, we used two independent ap-
proaches consisting of retroviral overexpression of a domi-
nant-negative form of STAT3 (STAT3D) and cell treatment with
a specific inhibitory peptide for STAT3 dimerization (STAT3pi)
(Turkson et al., 2001). Both STAT3D and STAT3pi reduced the
proliferation and migration of WT myoblasts and of IL-6/myo-
blasts treated with rIL-6 or with CM from WT myotubes (Figures
5D and 5E; Figures S4D–S4G). Thus, if STAT3 mediates the IL-6
effect on myoblast proliferation, the ectopic expression of a con-
stitutively active form of STAT3 (STAT3C) should be sufficient to
rescue the proliferation and migration defect of myoblasts
Cell Metabolism 7, 33–44, January 2008 ª2008 Elsevier Inc. 37
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Pathway Underlies the Proliferation Defect
of Myoblasts in the Absence of IL-6
(A) Activation of the STAT3, AKT, and ERK signal-
ing pathways was analyzed in WT and IL-6/ pri-
mary myoblasts, treated with or without rIL-6, by
western blotting using specific antibodies against
their phosphorylated forms.
(B) Percentage of BrdU-positive WT and IL-6/
primary myoblasts treated with or without rIL-6 in
the absence or presence of AG490 and wortman-
nin as indicated.
(C) Relative proliferation rates of WT and IL-6/
myoblasts in the presence of CM from WT or
IL-6/ myotubes, treated with or without AG490
and wortmannin where indicated, and expressed
as proliferation rate with respect to each cell
type in the presence of nonconditioned medium,
which was arbitrarily given a value of 1.
(D) Percentage of BrdU-positive WT and IL-6/
primary myoblasts treated with or without rIL-6 in
the absence or presence of a STAT3 inhibitor pep-
tide (STAT3pi) as indicated.
(E) Relative proliferation rates of WT and IL-6/
myoblasts in the presence of CM from WT myo-
tubes, treated with or without STAT3pi where indi-
cated, and expressed as proliferation rate with re-
spect to each cell type in the presence of
nonconditioned medium, which was arbitrarily
given a value of 1.
(F) Percentage of BrdU-positive WT and IL-6/
primary myoblasts treated with or without rIL-6
(left) or with CM from WT myotubes (right) in the
presence of a retroviral vector encoding a constitu-
tively active (MSCV-STAT3C) or negative (MSCV-
STAT3D) form of STAT3. Empty vector (MSCV)
was used as a control.
Data in (B)–(F) are mean ± SD. *p < 0.05 versus
control WT in (B), (D), and left panel of (F); *p <
0.05 versus each cell type in (C), (E), and right
panel of (F).lacking IL-6. Indeed, retroviral expression of STAT3C in IL-6/
myoblasts restored their proliferation and migration rates to
levels similar to those of WT cells (Figure 5F; Figures S4F and
S4G). Moreover, the proliferation andmigration of WTmyoblasts
were further enhanced by STAT3C (Figure 5F; Figure S4F). These
results demonstrate that IL-6 produced by myoblasts or myo-
tubes induces activation of STAT3, which is then required for
efficient myoblast proliferation and migration.
IL-6 and STAT3 Control Myoblast
Proliferation Gene Expression
Since STAT3 binding sites have been described in the promoters
of myoblast proliferation-associated cyclin D1 (Ccnd1) and
c-myc genes (Endo and Nadal-Ginard, 1986; Kiuchi et al.,
1999; Masuda et al., 2002; Wei and Paterson, 2001), we postu-
lated that their expression in myoblasts could be modulated by
38 Cell Metabolism 7, 33–44, January 2008 ª2008 Elsevier Inc.IL-6. RT-PCR analysis showed that cyclin D1 and c-myc levels
were reduced in myoblasts lacking IL-6 compared to WT myo-
blasts, and importantly, their levels were rescued by addition
of rIL-6 (Figure S5A) or CM fromWTmyotubes (data not shown).
To confirm that STAT3 activation specifically mediated the IL-6-
induced expression of these genes in proliferatingmyoblasts, we
analyzed their transcript levels in the presence or absence of
STAT3-specific inhibitors and activators. Retroviral delivery of
STAT3D and treatment with STAT3pi or AG490 reduced the ex-
pression of cyclin D1 and c-myc both inWTmyoblasts and in rIL-
6-treated IL-6/myoblasts (Figures S5B and S5C); conversely,
infection of IL-6-deficient myoblasts with STAT3C rescued the
lower expression of both genes (Figure S5C). No effect was ob-
served by addition of wortmannin (Figure S5B). Thus, IL-6 is nec-
essary for myoblast proliferation via activation of the STAT3
pathway, which in turn controls the expression of key cell
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sion of myoblast migration-associated gene products such as
the uPA receptor, uPAR (Plaur), and fibronectin (Fn1), whose
promoters harbor STAT3 binding sites and/or are regulated by
IL-6 (Birchmeier and Brohmann, 2000; Bonavaud et al., 1997;
Turner et al., 1983; Wells and Strickland, 1997), was also re-
duced in IL-6-deficient myoblasts compared to WT myoblasts
and was upregulated by the addition of rIL-6 (Figure S5D), sug-
gesting that their reduced expression may underlie, at least in
part, the migration defect of myoblasts lacking IL-6.
The IL-6/STAT3 Axis Regulates Satellite Cell Response
to Muscle Overloading
Based on the defective satellite cell proliferation after muscle
overloading in IL-6-deficient mice (see Figure 3B), we aimed to
confirm the relevance of the IL-6/STAT3 axis in the proliferation
of satellite cells during compensatory muscle growth. To this
end, we analyzed STAT3 activation in overloaded muscles of
WTand IL-6/mice usingbothwestern blotting and immunohis-
tochemical approaches. STAT3 expression and activation levels
were induced during CH in both genotypes as reflected by immu-
noblottingassays (FigureS6A). Incontrast, immunohistochemical
analysis revealed that the number of satellite cells coexpressing
MyoD and activated STAT3 was significantly reduced in IL-6/
muscle 3 days after overloading (Figure 6), in accordance with
the reduced presence of satellite cells coexpressing MyoD and
the proliferation marker p-H3 (see Figure 3B). These results are
in agreement with the in vitro data demonstrating that IL-6 in-
duces satellite cell proliferation through the activation of the
STAT3 pathway. Accordingly, IL-6 loss resulted in reduced ex-
pression of the proliferation- and migration-associated STAT3
target genes cyclin D1 and fibronectin in plantaris muscles 3
days after overloading (Figure 7A). Together, these results indi-
cate that loss of IL-6 results in normally activated satellite cells
that fail to proliferate early after thehypertrophic stimulus (3 days).
We next investigated the myogenic progression of satellite
cells from both WT and IL-6/mice during the course of the hy-
pertrophic growth process, at days 0, 3, 5, 7, 9, and 14 after over-
loading (Figure S7). We found that the number of satellite cells
expressing the activation marker MyoD increased at the earliest
time point after overloading in both WT and IL-6-deficient mus-
cles (Figure 3A; Figure S7). Importantly, while the number of sat-
ellite cells expressing MyoD increased at later time points after
overloading (5 and 7 days) in WT muscle in a proficient prolifer-
ative response, no increase was observed in the absence of
IL-6 (Figure S7), in agreement with the defective proliferation of
IL-6-deficient myoblasts in vitro. Reinforcing these data, no in-
crease in BrdU-positive cells was detected in IL-6-deficientmus-
cle at later time points after overloading (in conditions of daily
BrdU administration; data not shown), suggesting a persistent
block of cell proliferation in the absence of IL-6. In addition, the
time-dependent myogenic progression of satellite cells to further
differentiation stages was compromised in overloaded muscles
lacking IL-6, as evidenced by the impaired increase inmyogenin-
and embryonic myosin heavy chain (eMHC)-positive cells al-
ready detectable at early stages (Figures 7B and 7C; Figure S7)
and at late points after overloading (Figure S7) compared to WT
muscles. These results suggest that, in the absence of IL-6, the
deficient satellite cell differentiation after muscle overloadingmay be a consequence of the cell proliferation block, thereby
resulting in the abrogation of myofiber growth.
Altogether, these data demonstrate that IL-6 loss results in de-
ficient STAT3 signaling in activated satellite cells, leading to their
reduced proliferation and myogenic progression, and highlight
the major role played by the IL-6/STAT3 axis in controlling these
processes during compensatory hypertrophy.
DISCUSSION
The principal finding of this study is that IL-6 plays a critical role in
skeletal muscle hypertrophic growth. Our results have evidenced
that (1) skeletal muscle fibers strongly induce the local, transient
expression and releaseof IL-6 in response to ahypertrophic stim-
ulus; (2) muscle-produced IL-6 regulates muscle growth in vivo,
as shownby theblunted increaseofmyofiber size in acompensa-
tory hypertrophy model in IL-6-deficient mice; (3) the defective
growth is due to impaired proliferation—andmigration—of satel-
lite cells (muscle stemcells) affecting the subsequentmyonuclear
Figure 6. Loss of IL-6 Reduces STAT3 Activation after Muscle
Overloading
Sections of plantaris muscles obtained from WT and IL-6/mice after 3 days
of overloading were immunostained with antibodies against MyoD and
p-STAT3. Nuclei were detected with DAPI. Top: double immunostaining for
MyoD (green) and p-STAT3 (red) in overloaded muscles, illustrating the differ-
ent coexpression patterns in muscles from WT and IL-6/ mice. Arrows
indicate MyoD-positive cells; scale bar = 20 mm. Bottom: percentage of total
MyoD-positive cells coexpressing p-STAT3 in both genotypes. Data are
mean ± SD. *p < 0.05 versus WT.
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entiation-Associated Genes Is Reduced in IL-6/ Muscles
after Overloading
Plantaris muscle sections and mRNA were obtained from WT and
IL-6/ mice before and after 3 days of CH.
(A) Cyclin D1 (Ccnd1), c-myc, uPAR (Plaur), and fibronectin (Fn1)
mRNA expression levels were analyzed by qRT-PCR. Data are ex-
pressed as fold induction relative to control WT muscle.
(B) Myogenin (Myog) and eMHC (Myh3) mRNA expression levels were
analyzed by qRT-PCR. Data are expressed as in (A).
(C) Top: Representative confocal images of myogenin- and eMHC-
positive cells (red) in WT overloaded muscles. Myofiber outline is
shown by dystrophin staining (green), and nuclei are stained with
DAPI (blue). Scale bar = 25 mm. Bottom: quantification of myogenin-
and eMHC-positive cells in both genotypes.
Data are mean ± SD. *p < 0.05 versus WT.
pathway and its downstream targets p70S6K and 4E-BP1
by controlling net protein content is a crucial regulator of
skeletal muscle hypertrophic growth (Bodine et al., 2001;
Glass, 2003, 2005). Increasing evidence also demon-
strates that muscle hypertrophy is associated with and
dependent on the addition of new myonuclei via the pro-
liferation and further fusion of satellite cell-derived myo-
blasts to the adult myofiber (Dhawan and Rando, 2005;
O’Connor et al., 2007). However, the extracellular factors
and downstreammolecular signaling pathways responsi-
ble for satellite cell-mediated hypertrophy have not been
yet identified. The expression of IL-6 (a cytokine classi-
cally associated with the control of immune responses)
is induced in response to increased workload (Carson
et al., 2002) and skeletal muscle contraction during exer-
cise (Pedersen and Fischer, 2007); however, its potential
role in muscle hypertrophy was unknown. Our results
show that IL-6 expression is induced in growing myofib-
ers and associated satellite cells during compensatory
hypertrophy. Moreover, we demonstrate that IL-6 defi-
ciency results in blunted myofiber hypertrophic growth
accretion in the preexisting myofiber; (4) the growth defect is in-
deedmuscle cell intrinsic since loss of IL-6 results in reduced sat-
ellite cell-derived myoblast proliferation and migration, while
exogenously added IL-6 rescues these defects, andmore impor-
tantly, myotube-produced IL-6 also stimulatesmyoblast prolifer-
ation and migration, demonstrating autocrine and paracrine ac-
tions of IL-6 on muscle growth; and (5) the STAT3 pathway
emerges as the main effector of the growth-promoting action of
IL-6 onmuscle cells by controlling the expression of proliferation-
and migration-associated STAT3 target genes. These findings
provide insights into the mechanisms regulating the contribution
of satellite cells to physiological hypertrophy in adult muscles.
Notably, the beneficial function of local and transiently produced
IL-6 is opposed to the knownmuscle-wasting effect of infused IL-
6 or systemic high levels of IL-6 in cachectic conditions (Haddad
et al., 2005; Tisdale, 2005).
Skeletal muscles adapt to changes in their workload and activ-
ity by modifying their fiber size. The activation of the AKT/mTOR
40 Cell Metabolism 7, 33–44, January 2008 ª2008 Elsevier Inc.due to impaired satellite cell proliferation and further incorpora-
tion into preexisting myofibers after overloading in vivo. Signifi-
cantly, IL-6 gene deletion did not produce a reduction of fiber
size in adult mice in the basal state, indicating that the mecha-
nisms involved in maintenance of fiber size in mature muscles
are IL-6 independent. Elegant studies by Horsley et al. (2003)
have previously demonstrated that the cytokine IL-4 controls
new myofiber formation during injury-induced muscle regenera-
tion, a process recapitulating embryonic myogenesis, which is
mechanistically different from physiological adaptive growth of
preexisting normal myofibers in adult muscle (as in this study).
Horsley et al. (2003) found that during new myofiber formation,
IL-4 acts exclusively at the level of myoblast fusion with nascent
myotubes, without affecting prior myogenic stages. We show
that IL-6 controls satellite cell proliferation and migration, and
hence their ulterior incorporation to the hypertrophyingmyofiber,
suggesting different roles and mechanisms of action of both
cytokines in distinct skeletal muscle processes.
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tivation during injury-induced muscle inflammation and regener-
ation; however, this was ascribed to an IL-6-independent action
(Kami and Senba, 2002). Our results demonstrate that the levels
of activated STAT3, the primary STAT protein activated by liga-
tion of the IL-6 receptor (Kamimura et al., 2003; Kishimoto,
2005), are significantly reduced in IL-6-deficient myoblasts in
vitro. More importantly, STAT3 activation was also reduced in
satellite cells from IL-6/ muscles in vivo in response to over-
loading. We demonstrate that the reduced activation of STAT3
underlies the proliferation and migration defects of myoblasts
lacking IL-6, while ectopic activation of STAT3 restores both pro-
cesses. In accordance with our results, activation of STAT3 by
LIF, an IL-6 family member, has been shown to be essential for
stem cell self-renewal (Dani et al., 1998), while hyper-IL-6, a fu-
sion protein of soluble IL-6R and IL-6 that signals via gp130
homodimer receptors, can also sustain embryonic stem cell
self-renewal (Viswanathan et al., 2002).
We identified cyclin D1 as a STAT3 target gene product down-
regulated in satellite cells from IL-6-deficient muscle in vitro and
in vivo. Cyclin D1 is necessary for proliferation of different cell
types, including myogenic cells; in particular, myoblast prolifer-
ation and cell-cycle exit are critically dependent on the regulation
of the cyclin D1 gene in response to cellular growth signals (Kitz-
mann and Fernandez, 2001; Rao et al., 1994; Wei and Paterson,
2001). Thus, the reduced proliferation of myoblasts in the ab-
sence of IL-6 could be attributed to the reduced expression of
cyclin D1. Indeed, forced activation of STAT3 restored cyclin
D1 expression in IL-6/myoblasts concomitantly with their pro-
liferation capacity. Previous reports have demonstrated a regula-
tory role for the NF-kB and JNK/c-Jun pathways (Guttridge et al.,
1999; Perdiguero et al., 2007) in cyclin D1 gene transcription in
myoblasts in vitro. Our results provide an additional mechanism
underlying cyclin D1 gene expression in proliferating myoblasts
both in vitro and in vivo, via IL-6-induced STAT3 activation. Be-
sides controlling muscle-specific gene expression, the myo-
genic regulator MyoD can induce growth arrest in normal and
transformed cells independently of differentiation, at least in
part by inducing expression of the p21 gene (Cdkn1a) (Crescenzi
et al., 1990; Halevy et al., 1995; Sorrentino et al., 1990; Wei and
Paterson, 2001). An interaction of MyoD with STAT3 resulting in
impaired MyoD-mediated activities has been previously re-
ported in cell overexpression experiments (Kataoka et al.,
2003). Thus, in addition to downregulating cyclin D1, loss of
IL-6 may promote the myoblast growth-arresting function of
MyoD by restraining it from the inhibitory action of STAT3. Sup-
porting this possibility, the expression of the MyoD-inducible
p21 gene was induced in IL-6/ myoblasts in vitro and in over-
loaded IL-6/ muscles (see Figure S6B), which may contribute
to the observed reduced muscle cell proliferation. On the other
hand, migration of myoblasts in response to IL-6/STAT3 may
also constitute a necessary step for their incorporation into the
preexisting myofiber, leading to muscle growth, at least in part
by regulating the expression of the migration-associated gene
products fibronectin and uPAR. Interestingly, migratory func-
tions have also been attributed to cyclin D1 (Li et al., 2006) in ad-
dition to its classical cell-cycle-controlling role (Kitzmann and
Fernandez, 2001), thus suggesting that cyclin D1 may also con-
tribute to the promigratory action of IL-6 during muscle growth.The fact that IL-6 is produced not only by proliferating satellite
cells but also by growing myofibers during hypertrophy in vivo
suggests that IL-6 may also impact satellite cell proliferation—
and migration—during compensatory growth in a paracrine
fashion. Indeed, IL-6 produced by growing myotubes (and exog-
enous recombinant IL-6) stimulated the proliferative potential of
myoblasts in vitro. Most importantly, loss of IL-6 in overloaded
muscles prevents satellite cell myogenic progression, since the
normal transition of satellite cells froma proliferative to a differen-
tiated state is hampered during the hypertrophic process. We
further demonstrated that satellite cells can be normally acti-
vated after hypertrophic stimulus in the absence of IL-6, as evi-
denced by the similar number of MyoD-expressing cells at
3 days after overloading; however, they are incapable of further
proliferating and differentiating at subsequent stages during
the progression of the muscle growth process. Our results lead
us to propose that the reduced STAT3 activation in satellite cells
of IL-6-deficient muscles after overloading may play a causal
role in the subsequent block of satellite cell myogenic progres-
sion. Interestingly, since IL-6 production by nerve-mediated
skeletal muscle contraction has recently been shown to be partly
dependent on the activation of the calcineurin pathway (Banzet
et al., 2007) and since calcineurin is amajormediator of nerve ac-
tivity on muscle gene expression (Schiaffino and Serrano, 2002),
IL-6 may play a role as a factor released in response to neural
influences that promotes contraction-induced muscle growth.
Taken together, the results of this study demonstrate that IL-6
is necessary for adult hypertrophicmuscle growth in vivo and un-
veil a role for muscle-produced IL-6 as amajor regulator of satel-
lite cell proliferation andmyonuclear accretion.More importantly,
our data uncover the IL-6/STAT3 axis as a critical mechanism un-
derlying satellite cell proliferation-mediated hypertrophic muscle
growth. This mechanism is distinct from previously known adult
muscle cell-autonomous endogenous pathways, which stimu-
late protein synthesis. By identifying a pathway responsible for
controlling skeletal muscle hypertrophy, this work carries poten-
tial significance for the search for muscle atrophy therapies.
EXPERIMENTAL PROCEDURES
Animals
IL-6/mice, produced on the 129SvJ3 C57BL/6 background (WT) and gen-
erated by heterozygous mating of mice carrying a targeted disruption in which
the second exon in the IL-6 gene was replaced by a neor cassette (Kopf et al.,
1994), were generously provided by A. Bernad (Centro Nacional de Investiga-
ciones Cardiovasculares, Madrid). Mouse genotypes were confirmed by PCR
analysis of tail genomic DNA (Kopf et al., 1994). In vivo studies were performed
using male mice between 8 and 12 weeks of age.
Induction of Compensatory Muscle Growth
Animalswereanesthetizedwith ketamine/xylazine (80/10mg/kg, intraperitone-
ally), and compensatory hypertrophy (CH) of plantarismuscles was induced by
surgical section of the distal tendon of the medial and lateral gastrocnemius
muscle, which was folded back and sutured close to its proximal origin. This
procedure induces an adaptive growth response to functional overloading in
the soleus and plantarismuscles. Sham-operated limbswere used as controls.
In some experiments, to investigate cell proliferation during compensatory hy-
pertrophy, 30mg/kg/day BrdU (Sigma) in saline solution was injected intraper-
itoneally for 2days. At the indicated times, animalswere sacrificed andmuscles
were dissected, frozen in isopentane cooled with liquid nitrogen, and stored at
80C until analysis. A minimum of five animals of each genotype were
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were approved by the Catalan government Animal Care Committee.
Cell Culture
C2C12, IL-6-overexpressing C2C12 (C2/IL-6), and RAW264.7 cell lines were
cultured as described in Supplemental Data. Satellite cell-derived primary
myoblasts were obtained from muscles of WT and IL-6/ mice. Myoblast
isolation and culture were performed as described in Supplemental Data.
Reagents
Recombinant IL-6 (rIL-6, Peprotech; 10 ng/ml), a specific STAT3 inhibitor pep-
tide (STAT3pi, Calbiochem; 500 mM), a JAK/STAT inhibitor (AG490, Sigma;
50 mM), and a PI3K inhibitor (wortmannin, Sigma; 1 mM) were added to growth
medium (GM) or differentiation medium (DM) where indicated.
Transfections
For the generation of the stably transfected IL-6-overexpressing C2C12 cell
line (C2/IL-6), cells were transfected with the pBM6DraA6 (IL-6) expression
vector using Lipofectamine (Invitrogen) as described previously (Baeza-Raja
and Munoz-Canoves, 2004), and pools of G418-resistant colonies were
selected.
Proliferation
To detect S phase cells, cultures were pulsed with BrdU (Sigma) for 1 hr and
then processed and analyzed as described in Supplemental Data.
Migration Assays
To analyze cell migration ability, cultures were incubated in transwells and then
processed and quantified as described in Supplemental Data.
ELISA
Both primary and C2C12 myoblasts were cultured in GM (proliferating myo-
blasts) and for 48 hr in DM (myotubes). For the detection of IL-6 in cell culture
media andmuscle extracts, an ELISA kit (BDBiosciences) was used according
to the manufacturer’s instructions.
Western Blot Analysis
Lysate preparation andwestern blotting analysis were performed as described
in Supplemental Data.
Isolation of mRNA, RT-PCR, and qRT-PCR
RNA was analyzed by RT-PCR or quantitative RT-PCR (qRT-PCR). DNA
primers and details of the procedure are listed in Supplemental Data.
Retroviral Plasmids, Production, and Infection
MSCV, MSCV-STAT3C, and MSCV-STAT3D (McLemore et al., 2001) were
generously provided by D.C. Link (Washington University School of Medicine).
Retroviral infection was performed as described previously (Perdiguero et al.,
2007). Subconfluent cultures of primary myoblasts were infected by adding
medium containing the viral particles, 10 mM HEPES (pH 7.3), and 4 mg/ml of
polybrene to each plate. The medium was removed 24 hr later, and the cells
were then cultured as indicated.
Histology and Immunohistochemistry
Cryostat sections (10 mm thickness) from plantaris muscles of WT and IL-6/
mice were obtained before and after overloading at the indicated times. Sec-
tions were air dried and stored at 80C before processing for routine hema-
toxylin and eosin staining and immunohistochemical analyses. Immunodetec-
tion of IL-6, Pax7, MyoD, p-STAT3, myogenin, and eMHC was performed with
specific antibodies against IL-6 (AF-406-NA; R&D Systems), Pax7 (PAX7-c;
Developmental Studies Hybridoma Bank), MyoD (5.8A; DAKO), p-STAT3
Tyr705 (#9131; Cell Signaling Technology), myogenin (F5D, neat hybridoma
supernatant; Developmental Studies Hybridoma Bank), and eMHC (F1652,
neat hybridoma supernatant; Developmental Studies HybridomaBank). Quan-
tification of the number of myonuclei per myofiber was performed on sections
stained with primary specific antibody against dystrophin (MANDYS8; Sigma)
and DAPI. Labeling of cryosections with mouse monoclonal primary anti-
bodies was performed using the peroxidase or fluorescein M.O.M. Kit (Vector
42 Cell Metabolism 7, 33–44, January 2008 ª2008 Elsevier Inc.Laboratories) according to the manufacturer’s instructions. Double immunos-
tainings were performed with sequential addition of each primary and second-
ary antibody, employing appropriate positive and negative controls. Detection
of proliferating cells was performed with specific antibodies against BrdU (Ox-
fordBiotech) andp-H3Ser10 (MC463;Upstate) using intestinal tissue as a pos-
itive control. Sections were air dried, kept unfixed (Pax7 and eMHC) or fixed in
paraformaldehyde 2%–4%, washed in PBS, and incubated with primary anti-
bodies according to manufacturer’s instructions after blocking for 1 hr at room
temperature with a high-protein solution in PBS (Vector Laboratories). Subse-
quently, the slides were washed in PBS and incubated with appropriate sec-
ondary antibodies and labeling dyes. After washing, tissue sections were
mounted with Vectashield containing DAPI (Vector Laboratories).
Data Collection and Analysis
To measure myofiber cross-sectional area (CSA), plantaris muscles were cut
crosswise through the thickest part, and cryostat sections were stained with
hematoxylin and eosin. Muscle fiber size analyses; nuclei counts; and quantifi-
cation of the numbers of Pax7-, BrdU-, MyoD-, p-STAT3-, myogenin-, eMHC-,
and p-H3-positive cells were performed on images from muscle cross-sec-
tions. Micrographs were obtained using a Leica DMR microscope equipped
with a camera, and digitized images taken from different areas of cryosections
were analyzed. Individualmuscle fiberswereoutlined andCSAwasdetermined
using the image analysis software ImageJ 1.36b (http://rsb.info.nih.gov/ij/).
CSA analysis was performed on a total of 6586 myofibers. Myonuclei counts
wereperformedbycounting thenumberof nucleiwithin thedystrophin-positive
sarcolemma outline on pictures taken from control and overloaded plantaris
muscles. A total of 2326 fibers from both genotypes were analyzed. The total
number of BrdU-positive cells counted outside the dystrophin outline was
6649 and 2649 for overloaded muscles obtained 3 days after surgery from
WT and IL-6/ mice, respectively. No BrdU-positive cells were detected in
control muscles. Satellite cell detection was performed by determining the
number of Pax7-positive cells on at least four transversal sections obtained
at two different locations for each muscle. A total of 369 Pax7-positive cells
were analyzed. Data corresponding to the number of MyoD-positive cells in
WT and IL-6/ muscles at 3 days post-CH were obtained after counting 353
and 308 cells, respectively. At this time point, a total of 488 and 210 myoge-
nin-positive cells from WT and IL-6/ muscles were counted, respectively,
whereas the total number of eMHC-positive cells counted was 796 and 306
for WT and IL-6/ overloaded muscles, respectively.
Differences in fiber CSA were analyzed by nonparametric Wilcoxon signed-
ranks test using SPSS software. Statistical differences between pairs of sam-
ples were assessed by unpaired two-tailed Student’s t test. For all statistical
tests, the 0.05 level of confidence was accepted as statistically significant.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, two tables, and seven figures and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/7/1/33/DC1/.
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